Anti-Hypertensive Drugs - Jordan

Jordan

The Jordanian Anti-Hypertensive Drugs market is forecasted to achieve a revenue of US$6.38m in 2024.
It is anticipated that the market will experience an annual growth rate (CAGR 2024-2029) of -0.28%, leading to a market volume of US$6.29m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$12,290.00m in 2024.
Jordan's anti-hypertensive drug market is witnessing a surge in demand due to the country's growing aging population and increasing prevalence of hypertension.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Jordan has been on the rise in recent years.

Customer preferences: Jordan's population is aging, and the prevalence of hypertension is increasing as a result. As a result, there is a growing demand for Anti-Hypertensive Drugs in the country. Additionally, Jordan has a high prevalence of obesity, which is a major risk factor for hypertension. This has resulted in a greater demand for drugs that can help manage hypertension in overweight and obese patients.

Trends in the market: The Anti-Hypertensive Drugs market in Jordan is dominated by branded drugs, with a few generic drugs available. However, there has been a recent shift towards the use of generic drugs due to their lower cost. This trend is expected to continue as the government seeks to reduce healthcare spending.

Local special circumstances: Jordan's healthcare system is heavily subsidized by the government, with the majority of the population covered by the national health insurance scheme. However, the country's healthcare system is facing significant financial challenges, and the government has been forced to cut spending in recent years. This has led to a reduction in the number of drugs that are covered by the national health insurance scheme, which has made it more difficult for patients to access certain medications.

Underlying macroeconomic factors: Jordan's economy has been relatively stable in recent years, with moderate growth and low inflation. However, the country is facing significant economic challenges, including high unemployment and a large budget deficit. These challenges have put pressure on the government to reduce spending, including healthcare spending. As a result, there is a growing need for cost-effective drugs that can help manage hypertension in Jordan.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.